Cardiometabolic Disorders News

In patients with obesity and obstructive sleep apnea, those who had weight-loss surgery had approximately 40% reduced risk for major adverse CV events and death compared with those who did not, according to the results of the MOSAIC study.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

The past 10 years have seen rapid growth in research on how endocrine-disrupting chemicals affect humans.

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.

Hypertension expert and longtime editorial board member for Healio | Cardiology and Healio | Endocrinology George L. Bakris, MD, died June 15, 2024, at the age of 72.

The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.

Fewer U.S. adults aged 40 to 75 years are eligible for statin therapy for primary CVD prevention in the new PREVENT risk calculator compared with the older Pooled Cohort Equation, researchers reported.

PHILADELPHIA — Some dietary change may improve cardiometabolic measures beyond weight loss and providers should create a diet that will most benefit each individual with obesity, according to a speaker.

BOSTON — Lowering cardiovascular risk for people with type 2 diabetes requires effort from far beyond the clinician’s office, leveraging creative community partnerships that address social determinants of health, according to a speaker.

PHILADELPHIA — In this Healio video exclusive, Deepak L. Bhatt, MD, MPH, discusses two hot topics in cardiometabolic medicine: icosapent ethyl and sotagliflozin.